Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics, Inc. (NASDAQ:CLDX) posted its earnings results on Tuesday, May, 9th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.00. The business had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.57 million. Celldex Therapeutics had a negative return on equity of 53.10% and a negative net margin of 1,825.82%. View Celldex Therapeutics' Earnings History.

Celldex Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for Celldex Therapeutics.

8 brokers have issued twelve-month price targets for Celldex Therapeutics' shares. Their predictions range from $3.00 to $16.00. On average, they anticipate Celldex Therapeutics' share price to reach $7.42 in the next twelve months. View Analyst Ratings for Celldex Therapeutics.

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

• 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
• 2. Cowen and Company analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
• 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Celldex Therapeutics saw a decline in short interest during the month of June. As of June 30th, there was short interest totalling 14,517,219 shares, a decline of 16.0% from the June 15th total of 17,278,691 shares. Based on an average daily trading volume, of 1,915,959 shares, the days-to-cover ratio is presently 7.6 days. Currently, 11.7% of the company's stock are sold short.

Some companies that are related to Celldex Therapeutics include ANI Pharmaceuticals (ANIP), WAVE Life Sciences (WVE), ImmunoGen (IMGN), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), Inovio Pharmaceuticals (INO), Novavax (NVAX), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO), PDL BioPharma (PDLI), Celyad SA (CYAD), Concert Pharmaceuticals (CNCE), Puretech Health PLC (PRTC), Curis (CRIS), Idera Pharmaceuticals (IDRA), Advaxis (ADXS) and Codexis (CDXS).

Celldex Therapeutics' management team includes the folowing people:

• Larry Ellberger, Independent Chairman of the Board
• Anthony S. Marucci, President, Chief Executive Officer, Director
• Sam Martin, Chief Financial Officer, Senior Vice President
• Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer
• Thomas Andrew Davis M.D., Executive Vice President and Chief Medical Officer
• Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration
• Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
• Theresa M. LaVallee Ph.D., Senior Vice President - Regulatory and Precision Medicine
• Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer
• Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer`

Celldex Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (4.64%) and Creative Planning (0.06%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Avery W Catlin, Larry Ellberger and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.

Celldex Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Meditor Group Ltd and Creative Planning. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Larry Ellberger and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.36.